SEC Form 10-Q filed by NovoCure Limited

10/30/25 7:00:11 AM ET

Medical/Dental Instruments

Health Care

Get the next $NVCR alert in real time by email

nvcr-20250930

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_______________________________________________________

FORM 10-Q

(Mark One)


☒			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2025


☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 001-37565

NovoCure Limited

(Exact Name of Registrant as Specified in Its Charter)


Jersey						98-1057807
(State or Other Jurisdiction of						(I.R.S. Employer
Incorporation or Organization)						Identification No.)

No. 4 The Forum

Grenville Street

St. Helier, Jersey JE2 4UF

(Address of principal executive offices, including zip code)

+44 (0) 15 3475 6700

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name, Former Address and Former Fiscal Year, If Changed Since Last Report)

_______________________________________________________

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Ordinary Shares, no par value	NVCR	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐.

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

☒

Accelerated filer

☐

Non-accelerated filer

☐

Smaller reporting company

☐

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒.

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.


Class						Outstanding as of October 24, 2025
Ordinary shares, no par value						111,981,981 Shares

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

In addition to historical facts or statements of current condition, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements contained in this report are based on our current plans, expectations, hopes, beliefs, intentions or strategies concerning future developments and their impact on us. Forward-looking statements contained in this report constitute our expectations or forecasts of future events as of the date this report was filed with the Securities and Exchange Commission and are not statements of historical fact. You can identify these statements by the fact that they do not relate strictly to historical or current facts. Such statements may include words such as "anticipate," "will," "estimate," "expect," "project," "intend," "should," "plan," "believe," "hope," and other words and terms of similar meaning in connection with any discussion of, among other things, future operating or financial performance, strategic initiatives and business strategies, regulatory or competitive environments, our intellectual property and research and development related to our Tumor Treating Fields ("TTFields") devices marketed under various brand names, including "Optune Gio," "Optune Lua," and software, tools and other items to support and optimize the delivery of TTFields therapy (collectively, the "Products"). In particular, these forward-looking statements include, among others, statements about:

•our research and development, clinical study and commercialization activities and projected expenditures;

•the further commercialization of our Products for current and future indications;

•our business strategies and the expansion of our sales and marketing efforts in the United States ("U.S.") and in other countries;

•the market acceptance of our Products for current and future indications by patients, physicians, third-party payers and others in the healthcare and scientific community;

•our plans to pursue the use of our Products for the treatment of indications other than glioblastoma ("GBM"), non-small cell lung cancer ("NSCLC") and malignant pleural mesothelioma ("MPM");

•our estimates regarding revenues, expenses, capital requirements and needs for additional financing;

•our ability to obtain regulatory approvals for the use of our Products in indications other than GBM, NSCLC and MPM;

•our ability to acquire from third-party suppliers the supplies needed to manufacture our Products;

•our ability to manufacture adequate supply of our Products;

•our ability to secure and maintain adequate coverage from third-party payers to reimburse us for our Products for current and future indications;

•our ability to receive payment from third-party payers for use of our Products for current and future indications;

•our ability to maintain, develop, protect, defend or enforce our intellectual property position;

•our ability to manage the risks associated with business disruptions caused by natural disasters, extreme weather events, pandemics such as COVID-19 (coronavirus), international conflict, a prolonged failure of U.S. lawmakers to agree on a budget or appropriation legislation to fund the federal government’s operations (also known as a government shutdown), which could have an adverse effect on regulatory agencies, such as the U.S. Food and Drug Administration (e.g. PMA processing) and Centers for Medicare & Medicaid Services (e.g. payment processing), to perform their duties the impact our operations and the financial markets’ and other businesses’ reactions to any such failure, or other disruptions outside of our control;

•our cash needs; and

•our prospects, financial condition and results of operations.

These forward-looking statements involve a number of risks and uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Factors which may cause such differences to occur include those risks and uncertainties set forth under Part I, Item 1A., “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed on February 27, 2025, as well as other risks and uncertainties set

forth from time to time in the reports we file with the Securities and Exchange Commission (the "SEC"). In our prior filings, references to Optune now refer to Optune Gio® and NovoTTF-100L refer to Optune Lua®. We do not intend to update publicly any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

TRADEMARKS

This Quarterly Report on Form 10-Q includes trademarks of NovoCure Limited and other persons. All trademarks or trade names referred to herein are the property of their respective owners.


		Page
Cautionary Note Regarding Forward Looking Statements		i
Trademarks		ii

PART I—FINANCIAL INFORMATION

Item 1.	Financial Statements	2
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	19
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	30
Item 4.	Controls and Procedures	30

PART II—OTHER INFORMATION

Item 1.	Legal Proceedings	31
Item 1A.	Risk Factors	31
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	31
Item 3.	Defaults Upon Senior Securities	31
Item 4.	Mine Safety Disclosures	31
Item 5.	Other Information	31
Item 6.	Exhibits	32

	Signatures	33


NOVOCURE LIMITED AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS
U.S. dollars in thousands (except share data)
	September 30, 2025		December 31, 2024
	Unaudited		Audited
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	342,119	$	163,767
Short-term investments	691,382		796,106
Restricted cash	2,519		2,327
Trade receivables, net	85,230		74,226
Receivables and prepaid expenses	39,500		35,063
Inventories	39,104		35,086
Total current assets	1,199,854		1,106,575
LONG-TERM ASSETS:
Property and equipment, net	79,976		77,660
Field equipment, net	20,549		14,811
Right-of-use assets	48,402		27,120
Other long-term assets	12,413		14,618
Total long-term assets	161,340		134,209
TOTAL ASSETS	$	1,361,194	$	1,240,784

The accompanying notes are an integral part of these unaudited consolidated financial statements.


NOVOCURE LIMITED AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS
U.S. dollars in thousands (except share and per share data)
	Three months ended September 30,				Nine months ended September 30,				Year ended December 31,
	2025		2024		2025		2024		2024
	Unaudited				Unaudited				Audited
Net revenues	$	167,204	$	155,095	$	481,003	$	443,954	$	605,220
Cost of revenues	44,729		35,372		124,722		103,715		137,181
Gross profit	122,475		119,723		356,281		340,239		468,039

Operating costs and expenses:
Research, development and clinical studies	54,029		51,882		163,639		158,435		209,645
Sales and marketing	58,546		59,830		171,404		171,652		239,063
General and administrative	45,921		40,103		134,645		117,344		189,827
Total operating costs and expenses	158,496		151,815		469,688		447,431		638,535

Operating income (loss)	(36,021)		(32,092)		(113,407)		(107,192)		(170,496)
Financial income (expenses), net	5,999		10,507		18,111		31,236		39,334

Income (loss) before income tax	(30,022)		(21,585)		(95,296)		(75,956)		(131,162)
Income tax	7,248		8,985		16,432		26,749		37,465
Net income (loss)	$	(37,270)	$	(30,570)	$	(111,728)	$	(102,705)	$	(168,627)

Basic and diluted net income (loss) per ordinary share	$	(0.33)	$	(0.28)	$	(1.00)	$	(0.95)	$	(1.56)
Weighted average number of ordinary shares used in computing basic and diluted net income (loss) per share	111,908,252		108,247,716		111,259,532		107,679,501		107,834,368


CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
U.S. dollars in thousands
	Three months ended September 30,				Nine months ended September 30,				Year ended December 31,
	2025		2024		2025		2024		2024
	Unaudited				Unaudited				Audited
Net income (loss)	$	(37,270)	$	(30,570)	$	(111,728)	$	(102,705)	$	(168,627)
Other comprehensive income (loss), net of tax:
Change in foreign currency translation adjustments	(198)		64		121		(161)		(1,200)
Pension benefit plan	(499)		(1,927)		(427)		252		1,169
Total comprehensive income (loss)	$	(37,967)	$	(32,433)	$	(112,034)	$	(102,614)	$	(168,658)


NOVOCURE LIMITED AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
U.S. dollars in thousands (except share data)
	Ordinary shares	Additional paid-in capital		Accumulated other comprehensive income (loss)		Retained earnings (accumulated deficit)		Total shareholders' equity

Balance as of December 31, 2024 (audited)	108,516,819	$	1,519,809	$	(5,500)	$	(1,154,130)	$	360,179

Share-based compensation to employees	—	29,552		—		—		29,552
Exercise of options and vested RSUs	2,965,781	5,247		—		—		5,247
Other comprehensive income (loss), net of tax benefit of $0	—	—		1,299		—		1,299
Net income (loss)	—	—		—		(34,319)		(34,319)
Balance as of March 31, 2025 (Unaudited)	111,482,600	$	1,554,608	$	(4,201)	$	(1,188,449)	$	361,958

Share-based compensation to employees	—	26,143		—		—		26,143
Proceeds from issuance of shares	141,192	2,136		—		—		2,136
Exercise of options and vested RSUs	174,898	251				—		251
Other comprehensive income (loss), net of tax benefit of $0	—	—		(908)		—		(908)
Net income (loss)	—	—		—		(40,139)		(40,139)
Balance as of June 30, 2025 (Unaudited)	111,798,690	$	1,583,138	$	(5,109)	$	(1,228,588)	$	349,441

Share-based compensation to employees	—	29,321		—		—		29,321
Exercise of options and vested RSUs	181,291	538		—		—		538
Other comprehensive income (loss), net of tax benefit of $0	—	—		(697)		—		(697)
Net income (loss)	—	—		—		(37,270)		(37,270)
Balance as of September 30, 2025 (Unaudited)	111,979,981	$	1,612,997	$	(5,806)	$	(1,265,858)	$	341,333




	Ordinary shares	Additional paid-in capital		Accumulated other comprehensive loss		Retained earnings (accumulated deficit)		Total shareholders' equity

Balance as of December 31, 2023 (audited)	107,075,754	$	1,353,468	$	(5,469)	$	(985,503)	$	362,496

Share-based compensation to employees	—	34,084		—		—		34,084
Exercise of options and vested RSUs	528,020	213		—		—		213
Other comprehensive income (loss), net of tax benefit of $0	—	—		1,322		—		1,322
Net income (loss)	—	—		—		(38,760)		(38,760)
Balance as of March 31, 2024 (Unaudited)	107,603,774	$	1,387,765	$	(4,147)	$	(1,024,263)	$	359,355

Share-based compensation to employees	—	31,830		—		—		31,830
Proceeds from issuance of shares	178,668	2,187		—		—		2,187
Exercise of options and vested RSUs	231,388	1,121		—		—		1,121
Other comprehensive income (loss), net of tax benefit of $0	—	—		632		—		632
Net income (loss)	—	—		—		(33,375)		(33,375)
Balance as of June 30, 2024 (Unaudited)	108,013,830	$	1,422,903	$	(3,515)	$	(1,057,638)	$	361,750

Share-based compensation to employees	—	31,364		—		—		31,364
Exercise of options and vested RSUs	86,562	100		—		—		100
Other comprehensive income (loss), net of tax benefit of $0	—	—		(1,863)		—		(1,863)
Net income (loss)	—	—		—		(30,570)		(30,570)
Balance as of September 30, 2024 (Unaudited)	108,100,392	$	1,454,367	$	(5,378)	$	(1,088,208)	$	360,781


NOVOCURE LIMITED AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS
U.S. dollars in thousands

Cash, cash equivalents and restricted cash at the end of the period	$	344,638	$	189,199	$	344,638	$	189,199	$	166,094





Supplemental cash flow activities:
Cash paid during the period for:
Income taxes paid (refunded), net	$	3,430	$	6,637	$	22,239	$	17,053	$	23,463
Interest paid	$	2,843	$	2,964	$	8,162	$	4,934	$	7,714
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	$	342,119	$	185,422	$	342,119	$	185,422	$	163,767
Restricted cash	2,519		3,777		2,519		3,777		2,327
Total cash, cash equivalents and restricted cash	$	344,638	$	189,199	$	344,638	$	189,199	$	166,094
Non-cash activities:
Right-of-use assets obtained (disposed) in exchange for lease liabilities	$	2,678	$	757	$	27,788	$	(610)	$	494
Purchase of property incurred but unpaid at period end	$	370	$	201	$	370	$	201	$	1,619


	September 30, 2025
	Unaudited
	Fair value level	Adjusted cost basis		Unrealized gains		Unrealized losses		Fair market value		Recorded basis		Cash and cash equivalents		Short-term investments (2)
Cash		$	14,780	$	—	$	—	$	14,780	$	14,780	$	14,780	$	—
Money market funds	Level 1	256,410		—		—		256,410		256,410		256,410		—
Certificate of deposits and term deposits	Level 2	86,718		—		—		86,718		86,718		31,034		55,684
HTM securities (1)
U.S. Treasury bills	Level 1	$	119,302	$	45	$	—	119,347		119,302		$	39,895	$	79,407

Corporate debt securities	Level 2	$	556,291	$	195	$	(34)	556,452		556,291		$	—	$	556,291

		$	675,593	$	240	$	(34)	$	675,799	$	675,593	$	39,895	$	635,698

Total		$	1,033,501	$	240	$	(34)	$	1,033,707	$	1,033,501	$	342,119	$	691,382


	September 30, 2025		December 31, 2024
	Unaudited		Audited
Raw materials	$	4,598	$	4,004
Work in progress	4,805		7,969
Finished products	29,701		23,113
Total	$	39,104	$	35,086


	Three months ended September 30,				Nine months ended September 30,				Year ended December 31, 2024
	2025		2024		2025		2024
	Unaudited				Unaudited				Audited
Gain from redemption of Notes	—		—		—		(1,142)		(1,142)
Amortization of debt issuance costs	830		825		2,460		2,566		3,393
Total finance expenses (income) recognized	$	830	$	825	$	2,460	$	1,424	$	2,251


NOVOCURE LIMITED AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS
U.S. dollars in thousands
	Three months ended September 30,				Nine months ended September 30,				Year ended December 31,
	2025		2024		2025		2024		2024
	Unaudited				Unaudited				Audited
Cash flows from operating activities:
Net income (loss)	$	(37,270)	$	(30,570)	$	(111,728)	$	(102,705)	$	(168,627)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	3,663		2,458		10,432		8,131		11,235
Accrued Interest	789		(1,213)		4,436		60		(651)
Asset write-downs and impairment of field equipment	230		450		2,915		784		1,159
Share-based compensation	29,321		31,364		85,016		97,278		160,035
Foreign currency remeasurement loss (gain)	890		(503)		2,212		763		(227)
Decrease (increase) in accounts receivables and prepaid expenses	3,577		5,411		(15,476)		(8,983)		(26,358)
Amortization of discount (premium)	(6,402)		(6,737)		(19,516)		(18,972)		(25,644)
Decrease (increase) in inventories	886		1,895		(3,684)		(867)		2,568
Decrease (increase) in other long-term assets	2,490		1,906		6,480		7,969		7,395
Increase (decrease) in accounts payables and accrued expenses	24,830		7,452		10,517		(1,245)		19,106
Increase (decrease) in other long-term liabilities	(2,430)		(1,537)		(2,631)		(5,131)		(6,360)
Net cash provided by (used in) operating activities	$	20,574	$	10,376	(31,027)		(22,918)		(26,369)

Cash flows from investing activities:
Purchase of property, equipment and field equipment	$	(5,655)	$	(10,683)	(21,752)		(33,913)		(42,855)
Proceeds from maturity of short-term investments	185,000		190,000		725,000		608,000		778,000
Purchase of short-term investments	(107,909)		(169,124)		(602,298)		(692,118)		(875,387)
Net cash provided by (used in) investing activities	$	71,436	$	10,193	100,950		(118,031)		(140,242)

Cash flows from financing activities:
Proceeds from issuance of shares, net	$	—	$	—	2,136		2,187		4,150
Proceeds from senior secured credit facility, net	99,979		—		99,979		96,922		96,922
Repayment and redemption of long-term debt	—		—		—		(12,913)		(12,913)
Exercise of options	538		100		6,036		1,434		2,156
Net cash provided by (used in) financing activities	$	100,517	$	100	108,151		87,630		90,315

Effect of exchange rate changes on cash, cash equivalents and restricted cash	$	(22)	$	87	470		(46)		(174)

Increase (decrease) in cash, cash equivalents and restricted cash	192,505		20,756		178,544		(53,365)		(76,470)
Cash, cash equivalents and restricted cash at the beginning of the period	152,133		168,443		166,094		242,564		242,564


	September 30, 2025		December 31, 2024
	Unaudited		Audited
Liability component, net:
Principal amount	$	560,945	$	560,945
Unamortized issuance costs	(325)		(2,785)
Net carrying amount of liability component (1)	$	560,620	$	558,160

Presented as:
Short-term liability (2)	$	560,620	$	558,160


	September 30, 2025		December 31, 2024
	Unaudited		Audited
Liability component, net:
Principal amount	$	200,000	$	100,000
Unamortized issuance costs	(5,361)		(2,700)
Net carrying amount of liability component (1)	$	194,639	$	97,300


	Three months ended September 30,					Nine months ended September 30,				Year ended December 31,
	2025		0	2024		2025		2024		2024
United States	$	96,609		$	98,345	$	284,024	$	284,599	$	391,801
International markets:
Germany	20,286			16,990		58,078		47,834		65,263
France	19,620			15,243		55,895		39,998		55,730
Japan	9,385			8,581		27,578		24,062		32,569
Other international markets	15,706			11,311		40,622		32,053		42,471
International markets - Total	64,997			52,125		182,173		143,947		196,033

Greater China (1)	5,598			4,625		14,806		15,408		17,386

Total net revenues	$	167,204		$	155,095	$	481,003	$	443,954	$	605,220


	Nine months ended September 30, 2025
	Unaudited
	Number of options	Weighted average exercise price
Outstanding at beginning of year	11,315,468	$	31.41
Granted	944,888	17.96
Exercised	(422,673)	14.28
Forfeited and canceled	(843,581)	45.34
Outstanding as of September 30, 2025	10,994,102	$	29.84

Exercisable options	6,997,079	$	34.38


	Nine months ended September 30, 2025
	Unaudited
	Number of RSU/PSUs	Weighted average grant date fair value
Unvested at beginning of year	12,066,515	$	27.19
Granted	5,444,389	18.62
Vested	(2,899,297)	24.59
Forfeited and cancelled	(1,005,508)	34.56
Unvested as of September 30, 2025 (1)	13,606,099	23.77


September 30, 2025
Number of PSUs	Fair value at grant date per PSU		Total fair value at grant date
704,493	$	16.30	$	11,483
907,280	18.19		16,503
21,653	19.44		421
901,284	48.16		43,406
73,186	76.97		5,633


2,607,896			$	77,446


	September 30,
	2025			2024
	Optune Gio	Optune Lua	Total	Optune Gio		Optune Lua	Total
Active patients at period end (1)
United States	2,176	104	2,280	2,186		14	2,200
International markets:
Germany	595	31	626	558	520	12	570
France	499	—	499	393		—	393
Japan	474	—	474	437		—	437
Other international	533	4	537	506		7	513
International markets - Total	2,101	35	2,136	1,894		19	1,913

	4,277	139	4,416	4,080		33	4,113


						NovoCure Limited

Date: October 30, 2025						/s/ Christoph Brackmann
						Christoph Brackmann Chief Financial Officer (principal financial and accounting officer and duly authorized officer)

Date	Price Target	Rating	Analyst
7/25/2025	$14.50	Overweight → Equal Weight	Wells Fargo
7/8/2025	$30.00	Buy	Ladenburg Thalmann
12/2/2024	$18.00 → $30.00	In-line → Outperform	Evercore ISI
10/16/2024	$24.00 → $30.00	Neutral → Buy	H.C. Wainwright
11/20/2023	$15.00	Neutral	JP Morgan
8/28/2023	$85.00 → $25.00	Buy → Neutral	H.C. Wainwright
8/8/2023	$45.00	Neutral → Overweight	Piper Sandler
8/4/2023	$51.00	Outperform	SVB Securities

SEC Form 10-Q filed by NovoCure Limited

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for $NVCR

$NVCR Press Releases

Novocure Reports Third Quarter 2025 Financial Results

Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress

Novocure to Report Third Quarter 2025 Financial Results

$NVCR Insider Purchases

Chief Executive Officer Cordova Ashley bought $996,859 worth of Ordinary Shares (81,550 units at $12.22), increasing direct ownership by 23% to 437,569 units (SEC Form 4)

Chief Financial Officer Brackmann Christoph bought $231,800 worth of Ordinary Shares (20,000 units at $11.59), increasing direct ownership by 17% to 141,150 units (SEC Form 4)

$NVCR Insider Trading

Chief Financial Officer Brackmann Christoph covered exercise/tax liability with 7,033 units of Ordinary Shares, decreasing direct ownership by 5% to 134,117 units (SEC Form 4)

Chief Operating Officer Paravasthu Mukund covered exercise/tax liability with 3,117 units of Ordinary Shares, decreasing direct ownership by 4% to 80,439 units (SEC Form 4)

EVP, Pres., Novocure Oncology Leonard Frank X covered exercise/tax liability with 966 units of Ordinary Shares, decreasing direct ownership by 0.28% to 347,745 units (SEC Form 4)

$NVCR FDA approvals

October 18, 2024 - FDA Roundup: October 18, 2024

$NVCR Analyst Ratings

NovoCure downgraded by Wells Fargo with a new price target

Ladenburg Thalmann initiated coverage on NovoCure with a new price target

NovoCure upgraded by Evercore ISI with a new price target

$NVCR SEC Filings